Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
26/06/2026 15:11
BUZZ-Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal ** Shares of drugmaker Biogen BIIB.O rise 5.8% to $213.75 premarket
** Biogen says it has either paused or discontinued funding for most of the research programs included in its $5.6 billion acquisition of Apellis Pharmaceuticals' assets
** The U.S. drugmaker has also cut a small number of roles within the research organization as it shifts resources toward Empaveli and Syfovre, the approved therapies acquired through the deal
** The company did not offer details on the number of roles or the specific programs impacted by the decision
** Including session's move, BIIB shares up 20% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova